



Press Release

For immediate release

London Technology Fund invests in flu vaccine specialist Immune Targeting Systems

“Bridging the technology equity gap”

LONDON, UK, 16 July 2007 – London Technology Fund (LTF), London’s specialist investor in new technology companies, today announced it has completed an investment in Immune Targeting Systems (ITS) Limited, a company which is developing vaccines for mutating viruses. This is ITS’s first significant round of funding and LTF is the only UK investor in an international syndicate which is investing up to £3.5m. The syndicate includes Novartis Venture Fund (Switzerland), HealthCap (Sweden) and Truffle Capital (France). The London Development Agency will also be contributing an Exceptional Development Project award of £500,000 under the Grant for Research and Development scheme. As a result of the investment the company has been able to recruit its core team of development scientists and will move into dedicated facilities at the London BioScience Innovation Centre.

ITS’s novel vaccines will target the prevention and treatment of major life-threatening viral infections of global impact, initially seasonal and pandemic influenza, and followed by HIV/AIDS and Hepatitis C. Based on patented vaccine technology designed to target genetically diverse mutation-prone viruses, where cellular immunity is critical to disease protection, the vaccines should have broad efficacy across a wide range of virus strains and avoid the need to re-engineer the vaccine to target new virus strains. In the case of pandemic flu, it aims to offer governments the option of stockpiling vaccines which can be used as the first line of defence, giving time for strain-specific vaccines to be manufactured.

Carlton Brown, CEO of ITS, commented: *“We are delighted to have raised investment from such a strong syndicate of specialist investors including LTF. It will enable us to accelerate and further develop our technology to target these important diseases. LTF’s support throughout has been valuable to us and greatly helped in co-ordinating a diverse syndicate and retaining momentum behind the investment process”.*

David M^cMeekin, Chairman of LTF, said: “*We have been impressed with Carlton’s perseverance in bringing this funding round to a successful conclusion and are pleased that ITS has now secured the support that it needs to continue the development of its important vaccine technology*”.

Contact details

Immune Targeting Systems Ltd

Carlton Brown, Founder and Chief Executive

+44 (0)7970 944 454
London Bioscience Innovation Centre
2 Royal College Street
London NW1 0NH

London Technology Fund

David M^cMeekin, Chairman

+44 (0)20 7247 6300
Company Guides Venture Partners Ltd
13 Christopher Street
London EC2A 2BS

- Notes to editors -

1. Immune Targeting Systems

www.its-innovation.co.uk

Immune Targeting Systems (ITS) Ltd is a London based life science company developing synthetic vaccines for mutating viruses. The vaccine candidates are designed to be potent stimulators of antiviral cellular immunity and belong to a clinically validated vaccine subclass. ITS’s lead pandemic flu vaccine targets all potential pandemic and seasonal flu strains. This is designed to offer governments a first line of vaccine defence which would be immediately deployable. The Company also has other candidates for all major strains of HIV/AIDS and Hepatitis-C (genotype-1). These viruses share a number of common features which present major challenges to vaccine designers: they exist in many genetically diverse strains, have a tendency to mutate continually and cause human disease which can be prevented by generating appropriate cellular immune response. ITS has specifically developed its vaccine technologies to address these major vaccine challenges.

2. London Technology Fund

www.londontechnologyfund.com

The London Technology Fund (LTF) is London’s specialist investor in new technology companies. It is focused on the funding gap for new, high growth technology companies based in Greater London. It bridges the funding gap by leading and building a syndicate of investors or by completing the gap in an existing syndicate. The Fund is happy to work with investors already known to a company or to help entrepreneurs find investors. It has developed a streamlined investment process with an initial web-based application that helps entrepreneurs identify and provide the essential information needed for prompt decision-making.

The Fund can invest in a series of tranches over a number of years alongside other investors, contributing up to a maximum of £1.5m from its own resources to the total investment made in a single company. The London Technology Fund is funded by the London Development Agency and the European Regional Development Fund. It is managed by Company Guides Venture Partners Ltd, which is authorised and regulated by the Financial Services Authority.

- E N D -